Medical School · Year 1 · Foundations · includes a quiz and discussion video

Lecture 9: Nucleotide Metabolism

Unit 1.1: Foundations of Medicine & Medical Sciences

Learning Objectives

By the end of this lecture, students will be able to:

1. Outline the de novo synthesis pathways for purine and pyrimidine nucleotides
2. Describe the salvage pathways and their clinical importance
3. Explain the regulation of nucleotide biosynthesis
4. Identify the degradation pathways for purines and pyrimidines
5. Describe clinical disorders of nucleotide metabolism including gout and immunodeficiency syndromes
6. Explain the mechanism of action of antimetabolite drugs that target nucleotide synthesis

Lecture Content

I. Introduction to Nucleotides

Nucleotides are among the most versatile molecules in biochemistry, serving functions far beyond their role as the building blocks of nucleic acids. Each nucleotide consists of three components: a nitrogenous base (purine or pyrimidine), a five-carbon pentose sugar (ribose in ribonucleotides or 2'-deoxyribose in deoxyribonucleotides), and one to three phosphate groups.

The functions of nucleotides span nearly every aspect of cellular metabolism. As monomers, they polymerize to form DNA and RNA, the molecules of genetic information and its expression. Nucleoside triphosphates—particularly ATP and GTP—serve as the universal energy currency, coupling energetically unfavorable reactions to ATP hydrolysis. The cyclic nucleotides cAMP and cGMP function as second messengers in signal transduction. Many essential coenzymes incorporate nucleotide structures: NAD⁺ and FAD carry electrons in redox reactions, while coenzyme A carries acyl groups. Nucleotides also activate substrates for biosynthetic reactions—UDP-glucose for glycogenesis, CDP-choline for phospholipid synthesis.

The nitrogenous bases fall into two structural categories. Purines—adenine (A) and guanine (G)—possess a double-ring structure formed by fusing a pyrimidine ring to an imidazole ring. Pyrimidines—cytosine (C), thymine (T), and uracil (U)—contain a single six-membered ring. In DNA, the base pairs are adenine-thymine (A-T) and guanine-cytosine (G-C). In RNA, uracil replaces thymine, pairing with adenine.

<image>Panel A: Purines adenine and guanine as double-ring structures with IUPAC atom numbering and characteristic amino groups and carbonyl oxygens highlighted. Panel B: Pyrimidines cytosine, thymine, uracil as single six-membered rings with thymine methyl group at C5 highlighted and DNA/RNA labels. Panel C: Color scheme distinguishing hydrogen bond donors (blue) from acceptors (red) on all five bases. Panel D: Watson-Crick base pair inset showing A-T with 2 hydrogen bonds and G-C with 3 hydrogen bonds.</image>

II. De Novo Purine Synthesis

The de novo synthesis of purine nucleotides is a complex, energy-demanding process that occurs in the cytoplasm of most cells. Unlike pyrimidine synthesis, where the ring is constructed first and then attached to ribose, purine synthesis builds the ring directly onto the ribose phosphate scaffold.

Formation of PRPP: The Common Precursor

The pathway begins with the synthesis of 5-phosphoribosyl-1-pyrophosphate (PRPP) from ribose-5-phosphate. PRPP synthetase transfers a pyrophosphate group from ATP to the C1 position of ribose-5-phosphate. PRPP is a critically important metabolite—it serves not only as the starting point for purine de novo synthesis but also for pyrimidine synthesis (at a later step) and for salvage pathway reactions that recycle free bases.

The Committed Step: Glutamine-PRPP Amidotransferase

The first committed step of purine synthesis—the point of no return—is catalyzed by glutamine-PRPP amidotransferase. This enzyme displaces the pyrophosphate of PRPP with an amino group donated by glutamine, generating 5-phosphoribosylamine. This reaction is essentially irreversible and represents the major regulatory point for the pathway. The enzyme is feedback-inhibited by the end products AMP, GMP, and IMP, ensuring that purine synthesis slows when nucleotide pools are adequate.

Building the Purine Ring

The purine ring is assembled through ten enzymatic steps that sequentially add atoms from multiple sources. This "assembly on a scaffold" strategy contributes atoms from five different donors. Glycine contributes carbons 4 and 5 and nitrogen 7—essentially, an entire glycine molecule is incorporated. The two formyl carbons (C2 and C8) derive from N¹⁰-formyl-tetrahydrofolate, linking purine synthesis to folate metabolism. Glutamine provides nitrogens N3 and N9 through its amide group. Aspartate donates N1. Carbon 6 comes from CO₂ (as bicarbonate).

The final product of the ten-step pathway is inosine monophosphate (IMP), which contains the base hypoxanthine—the "parent" purine from which both AMP and GMP are derived.

<image>Panel A: Purine ring with atoms color-coded: N1 red (aspartate), C2/C8 purple (N10-formyl-THF), N3/N9 green (glutamine amide N). Panel B: C4/C5/N7 blue (glycine entire molecule) and C6 yellow (CO2 bicarbonate) completing atom sources. Panel C: Reaction sequence from ribose-5-P to PRPP (PRPP synthetase) to 5-phosphoribosylamine (glutamine-PRPP amidotransferase committed step). Panel D: Ten steps to IMP with feedback inhibition from AMP, GMP, IMP acting on amidotransferase.</image>

Conversion of IMP to AMP and GMP

IMP sits at a branch point, and its conversion to AMP or GMP requires different pathways. The synthesis of AMP proceeds through adenylosuccinate: IMP reacts with aspartate (requiring GTP) to form adenylosuccinate, which is then cleaved by adenylosuccinate lyase to release AMP and fumarate.

The synthesis of GMP proceeds through xanthosine monophosphate (XMP): IMP is first oxidized by IMP dehydrogenase (consuming NAD⁺) to form XMP, which then receives an amino group from glutamine (requiring ATP) to form GMP.

A elegant reciprocal regulation emerges from the energy requirements of these pathways: GTP is required to make AMP, while ATP is required to make GMP. This cross-dependence ensures balanced production—if GTP is abundant, more AMP will be made, and vice versa. Additionally, each product inhibits its own synthesis while the precursor IMP accumulates and flows toward the other product.

III. De Novo Pyrimidine Synthesis

Pyrimidine biosynthesis follows a fundamentally different strategy from purine synthesis. Rather than building the ring on a ribose scaffold, the pyrimidine ring is first assembled as a free molecule (orotic acid) and only then attached to ribose-5-phosphate.

The CAD Trifunctional Enzyme

In mammals, the first three enzymatic activities of pyrimidine synthesis are catalyzed by a single trifunctional enzyme called CAD—an acronym for its three activities: Carbamoyl phosphate synthetase II, Aspartate transcarbamoylase, and Dihydroorotase.

The committed step is catalyzed by carbamoyl phosphate synthetase II (CPS-II), which synthesizes carbamoyl phosphate from glutamine, CO₂, and two ATP molecules. This cytoplasmic enzyme is distinct from CPS-I, the mitochondrial enzyme involved in the urea cycle—CPS-I uses ammonia rather than glutamine and functions in nitrogen disposal rather than biosynthesis.

Aspartate transcarbamoylase (ATCase) then condenses carbamoyl phosphate with aspartate to form carbamoyl aspartate. Dihydroorotase cyclizes carbamoyl aspartate to form dihydroorotate, completing the pyrimidine ring structure.

Formation of UMP

Dihydroorotate is oxidized to orotate by dihydroorotate dehydrogenase, located on the outer surface of the inner mitochondrial membrane. This is the only mitochondrial step in pyrimidine synthesis and links the pathway to the respiratory chain.

The final two reactions attach the pyrimidine ring to ribose and complete UMP synthesis. These activities reside on a single bifunctional enzyme called UMP synthase. Orotate phosphoribosyltransferase attaches orotate to PRPP, forming orotidine-5'-monophosphate (OMP). OMP decarboxylase then removes CO₂ to generate UMP—the parent pyrimidine nucleotide from which all others derive.

<image>Panel A: CAD trifunctional enzyme with CPS-II domain receiving CO2 + glutamine + 2 ATP producing carbamoyl phosphate. Panel B: ATCase domain forming carbamoyl aspartate from aspartate, dihydroorotase cyclizing to dihydroorotate. Panel C: Dihydroorotate crossing membrane to mitochondrial dehydrogenase producing orotate, returning to cytoplasm for UMP synthase. Panel D: UMP synthase converting orotate + PRPP to OMP then UMP with regulatory points: CPS-II inhibited by UTP, ATCase inhibited by CTP.</image>

Formation of Other Pyrimidines

UMP is phosphorylated by kinases to form UDP and then UTP. CTP synthetase converts UTP to CTP by replacing the carbonyl oxygen at C4 with an amino group, using glutamine as the nitrogen donor.

IV. Deoxyribonucleotide Synthesis

DNA synthesis requires deoxyribonucleotides (dNTPs), which differ from their ribonucleotide counterparts in lacking the 2'-hydroxyl group on the sugar. A single enzyme, ribonucleotide reductase (RNR), catalyzes the reduction of ribonucleoside diphosphates (NDPs) to deoxyribonucleoside diphosphates (dNDPs).

Ribonucleotide Reductase: Structure and Mechanism

Ribonucleotide reductase reduces the ribose ring at the C2' position, replacing the hydroxyl with hydrogen. The enzyme contains a unique free radical (tyrosyl radical) essential for catalysis. The reducing equivalents ultimately derive from NADPH, but they are transferred through a series of carriers: NADPH reduces thioredoxin (or glutaredoxin), which in turn reduces ribonucleotide reductase.

Regulation of dNTP Pools

Maintaining balanced dNTP pools is essential for accurate DNA replication; imbalanced pools cause mutations. Ribonucleotide reductase achieves this balance through two distinct regulatory sites. The activity site controls overall enzyme activity: ATP binding activates the enzyme, while dATP binding inhibits it. This makes sense—ATP signals energy abundance and growth potential, while accumulation of dATP indicates that deoxyribonucleotides are plentiful.

The specificity site determines which particular NDP is reduced at any moment. Binding of different effectors (ATP, dATP, dTTP, dGTP) at this site alters substrate preference, channeling reducing activity toward whichever dNTP is needed.

Thymidylate Synthesis

Thymine nucleotides present a special case. Thymidine (deoxythymidine) exists only as a deoxyribonucleotide—there is no "UTP to TTP" conversion analogous to the UTP-to-CTP reaction. Instead, dUMP is methylated to dTMP by thymidylate synthase.

This reaction requires N⁵,N¹⁰-methylene-tetrahydrofolate as the methyl donor. Importantly, the folate coenzyme is not merely a methyl donor but is itself oxidized in the reaction, being converted to dihydrofolate (DHF). To regenerate the active tetrahydrofolate (THF), cells require dihydrofolate reductase (DHFR), which reduces DHF to THF using NADPH. This linkage to folate metabolism makes thymidylate synthesis vulnerable to antifolate drugs.

<image>Panel A: Thymidylate synthase converting dUMP to dTMP with N5,N10-methylene-THF providing methyl group (red highlight). Panel B: Dihydrofolate exiting reaction, DHFR reducing DHF back to THF using NADPH. Panel C: Serine hydroxymethyltransferase regenerating methylene-THF from THF completing the cycle. Panel D: Drug targets box showing methotrexate/trimethoprim inhibiting DHFR and 5-FU inhibiting thymidylate synthase causing thymineless death.</image>

V. Salvage Pathways

While de novo synthesis can produce nucleotides from simple precursors, it is energetically expensive. Salvage pathways offer a more economical alternative by recycling the purine and pyrimidine bases released during nucleic acid turnover, attaching them directly to PRPP to regenerate nucleotides.

Purine Salvage: HGPRT and APRT

Two key enzymes mediate purine salvage. Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) converts hypoxanthine to IMP and guanine to GMP, using PRPP as the ribose-5-phosphate donor and releasing pyrophosphate. Adenine phosphoribosyltransferase (APRT) similarly converts adenine to AMP.

Purine salvage is particularly important in certain tissues. The brain has limited capacity for de novo purine synthesis and depends heavily on salvage. Red blood cells, lacking nuclei and the ability to synthesize proteins, cannot perform de novo synthesis at all and rely entirely on salvage to maintain their nucleotide pools. The importance of salvage is dramatically illustrated by the severe consequences of HGPRT deficiency (Lesch-Nyhan syndrome).

Pyrimidine Salvage

Pyrimidine salvage pathways are less prominent than purine salvage, partly because pyrimidine degradation products are more completely catabolized. Nonetheless, pyrimidine nucleoside kinases can phosphorylate uridine to UMP and thymidine to dTMP, conserving these bases when available.

VI. Nucleotide Degradation

Nucleotides that are not recycled are degraded, with purines and pyrimidines following very different fates.

Purine Degradation: The Path to Uric Acid

Purine degradation converges on a common pathway leading to uric acid. Adenine nucleotides are first deaminated: AMP can be deaminated to IMP, or adenosine can be deaminated to inosine by adenosine deaminase (ADA). The nucleosides are then cleaved by purine nucleoside phosphorylase (PNP) to release the free bases hypoxanthine (from adenine nucleotides) and guanine (from guanine nucleotides). Guanine is deaminated to xanthine.

Both hypoxanthine and xanthine are substrates for xanthine oxidase, which oxidizes hypoxanthine to xanthine and xanthine to uric acid. In humans, uric acid is the end product of purine catabolism—we lack uricase, the enzyme that further degrades uric acid to the more soluble allantoin found in most other mammals.

Uric acid has limited water solubility, particularly at the acidic pH found in urine. When blood uric acid levels rise (hyperuricemia), crystals can precipitate in joints and tissues, causing gout and related disorders. The kidneys excrete most uric acid, and impaired renal excretion is a common cause of hyperuricemia.

<image>Panel A: Left branch showing AMP to IMP (AMP deaminase) to inosine to hypoxanthine via PNP. Panel B: Right branch showing GMP to guanosine to guanine (PNP) to xanthine via guanase. Panel C: Convergence with xanthine oxidase oxidizing hypoxanthine to xanthine to uric acid with allopurinol/febuxostat inhibition noted. Panel D: Uric acid structure with poor solubility note, humans lack uricase clinical note, and needle-shaped urate crystals under polarized light inset.</image>

Pyrimidine Degradation: Soluble End Products

Pyrimidine degradation takes a completely different course. The pyrimidine ring is opened and broken down to small, water-soluble products that are easily excreted or further metabolized. Cytosine is deaminated to uracil, and both uracil and thymine undergo reduction to dihydropyrimidines. Further catabolism releases ammonia and CO₂, leaving β-alanine (from uracil and cytosine) or β-aminoisobutyrate (from thymine). These amino acids can be further metabolized or excreted without causing solubility problems—pyrimidine degradation produces no equivalent of gout.

VII. Regulation of Nucleotide Metabolism

The synthesis of nucleotides is tightly regulated to maintain balanced pools while avoiding wasteful overproduction. Both de novo and salvage pathways respond to the levels of nucleotide end products.

Purine Synthesis Regulation

PRPP synthetase is activated by inorganic phosphate and inhibited by purine nucleotides (AMP, GMP, ADP, GDP). When purine nucleotides are abundant, less PRPP is made, limiting substrate for both de novo and salvage pathways.

The committed step—glutamine-PRPP amidotransferase—is feedback-inhibited by all three purine nucleotides: AMP, GMP, and IMP. This enzyme contains two distinct inhibitory sites that can bind different nucleotides, and inhibition is synergistic when both sites are occupied.

The branch point from IMP to AMP and GMP features reciprocal regulation. GTP is required for AMP synthesis, and ATP is required for GMP synthesis. This ensures that neither product can accumulate excessively without promoting synthesis of the other.

Pyrimidine Synthesis Regulation

CPS-II, catalyzing the committed step, is inhibited by UTP (the pathway's end product) and activated by ATP and PRPP. High ATP signals energy abundance and activates nucleotide synthesis generally, while high PRPP indicates that ribose-5-phosphate is available for nucleotide construction.

ATCase, the second step in pyrimidine synthesis, is activated by ATP and inhibited by CTP. This regulation makes physiological sense: ATP abundance signals favorable conditions for growth and DNA replication, while CTP accumulation indicates that pyrimidines are sufficient.

VIII. Clinical Correlations

Gout

Gout results from the deposition of monosodium urate crystals in joints and soft tissues when blood uric acid levels exceed solubility limits. The crystals trigger an intense inflammatory response, causing the excruciatingly painful acute gouty arthritis classically affecting the first metatarsophalangeal joint (podagra). Chronic gout leads to tophi—deposits of urate crystals in tissues including cartilage, tendons, and skin.

Hyperuricemia can result from overproduction of uric acid (increased purine synthesis or turnover, as in myeloproliferative disorders or tumor lysis syndrome) or underexcretion (the more common cause, often related to renal impairment or medications such as thiazide diuretics).

Treatment approaches include xanthine oxidase inhibitors (allopurinol, febuxostat) to reduce uric acid production, uricosuric agents (probenecid) to increase renal excretion, and anti-inflammatory medications (colchicine, NSAIDs, corticosteroids) for acute attacks. Dietary modification—limiting purine-rich foods and alcohol—provides modest benefit.

Lesch-Nyhan Syndrome

Lesch-Nyhan syndrome results from deficiency of HGPRT, the enzyme that salvages hypoxanthine and guanine. This X-linked recessive disorder affects males almost exclusively. Without functional salvage, PRPP accumulates and drives excessive de novo purine synthesis. The increased purine production leads to dramatic hyperuricemia and gout in childhood.

Beyond the metabolic consequences, Lesch-Nyhan syndrome causes profound neurological dysfunction including intellectual disability, spasticity, and choreoathetosis. Most strikingly, affected individuals exhibit compulsive self-injurious behavior, particularly biting their lips and fingers. The mechanism connecting HGPRT deficiency to these neurological features remains incompletely understood but may involve dopaminergic dysfunction.

Immunodeficiency Syndromes

Adenosine deaminase (ADA) deficiency causes one form of severe combined immunodeficiency (SCID). Without ADA, deoxyadenosine accumulates and is phosphorylated to dATP. High dATP inhibits ribonucleotide reductase, blocking the synthesis of all deoxyribonucleotides. Lymphocytes—which proliferate rapidly and depend on robust DNA synthesis—are particularly vulnerable, leading to combined T and B cell deficiency. Treatment options include enzyme replacement (pegylated ADA) and gene therapy, which has proven successful in many cases.

Purine nucleoside phosphorylase (PNP) deficiency similarly causes accumulation of dGTP, primarily affecting T cells and causing T cell immunodeficiency with relatively preserved B cell function.

Orotic Aciduria

Orotic aciduria results from deficiency of UMP synthase, the bifunctional enzyme catalyzing the last two steps of pyrimidine de novo synthesis. Orotate accumulates and spills into the urine. Patients develop megaloblastic anemia—because pyrimidine deficiency impairs DNA synthesis and cell division—but unlike the megaloblastic anemia of folate or B₁₂ deficiency, orotic aciduria does not respond to these vitamins. Treatment with oral uridine bypasses the block and effectively corrects the anemia.

IX. Pharmacology: Antimetabolites

The dependence of rapidly dividing cells on nucleotide synthesis makes these pathways attractive targets for cancer chemotherapy and immunosuppression.

Folate Antagonists

Methotrexate inhibits dihydrofolate reductase (DHFR), preventing regeneration of tetrahydrofolate. Without THF, cells cannot synthesize thymidylate (thymidine nucleotides) or complete purine synthesis (which requires formyl-THF). The resulting "thymineless death" preferentially kills rapidly dividing cells. Methotrexate is used in cancer chemotherapy and at lower doses in autoimmune diseases including rheumatoid arthritis.

Trimethoprim also inhibits DHFR but has much higher affinity for the bacterial enzyme than the mammalian enzyme, making it useful as a selective antibiotic often combined with sulfamethoxazole.

Thymidylate Synthase Inhibitors

5-Fluorouracil (5-FU) is converted in cells to 5-fluoro-dUMP, which covalently and irreversibly inhibits thymidylate synthase. The fluorine atom prevents the normal elimination step in the reaction mechanism, trapping the enzyme in an inactive state. 5-FU is widely used in gastrointestinal and breast cancers.

Purine Antimetabolites

6-Mercaptopurine (6-MP) and its prodrug azathioprine are purine analogs that inhibit multiple steps in purine synthesis and are also incorporated into DNA, where they disrupt replication. 6-MP is used in acute lymphoblastic leukemia and as an immunosuppressant for autoimmune diseases and transplant rejection.

<image>Panel A: DHFR with methotrexate and trimethoprim blocking THF regeneration; drug box for cancer/autoimmune and antibiotic uses. Panel B: Thymidylate synthase with 5-FU blocking dTMP synthesis; drug box for colorectal/breast cancer. Panel C: Purine synthesis with 6-MP blocking multiple steps; drug box for leukemia/immunosuppression; ribonucleotide reductase with hydroxyurea for myeloproliferative disorders. Panel D: Arrows tracing drug to target to DNA synthesis blockade with therapeutic principle: rapidly dividing cells preferentially affected.</image>

Summary

Nucleotide metabolism encompasses the synthesis, salvage, and degradation of purine and pyrimidine nucleotides essential for DNA and RNA synthesis and numerous other cellular functions. De novo purine synthesis builds the ring directly on a ribose phosphate scaffold through ten steps, producing IMP, which is converted to AMP or GMP. De novo pyrimidine synthesis first assembles the ring (as orotate) and then attaches it to ribose, ultimately producing UMP. Salvage pathways recycle free bases using PRPP—HGPRT salvages hypoxanthine and guanine, while APRT salvages adenine. Ribonucleotide reductase converts ribonucleotides to deoxyribonucleotides for DNA synthesis, with thymidylate synthase specifically making dTMP from dUMP. Purine degradation leads to uric acid, whose accumulation causes gout; pyrimidines degrade to water-soluble products. HGPRT deficiency causes Lesch-Nyhan syndrome; ADA deficiency causes SCID. Antimetabolite drugs targeting nucleotide synthesis—including methotrexate, 5-fluorouracil, and 6-mercaptopurine—are important in cancer chemotherapy and immunosuppression.

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown